Link to this page
Physician Data Query
| Preferred Name | bosutinib | |
| Synonyms |
SKI-606 4-anilino-3-quinolinecarbonitrile 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Bosulif 4-anilinobenzo(g)quinoline-3-carbonitrile |
|
| Definitions |
A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C60809" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C60809" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000467222 |
|
| altLabel |
SKI-606 4-anilino-3-quinolinecarbonitrile 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Bosulif 4-anilinobenzo(g)quinoline-3-carbonitrile
|
|
| cui |
C1831731 C1174836 C3496923
|
|
| DATE FIRST PUBLISHED |
2006-02-21
|
|
| Date last modified |
2012-09-05
|
|
| definition |
A synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C60809" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C60809" NCI Thesaurus)
|
|
| LT |
TRD
|
|
| NCI ID |
C60809
|
|
| notation |
CDR0000467222
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
bosutinib
|
|
| tui |
T109 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |